Artios Pharma
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. Its clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Polθ) inhibitor ART6043, as well as its preclinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell’s remaining survival mechanisms.
Domain
artiospharma.com
Country
United KingdomIndustry
BiopharmaEmployees
51-100
Last Funding
$115.0M
Founded
2015
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does Artios Pharma use?+
We have not yet detected technologies for Artios Pharma.
What industry is Artios Pharma in?+
Artios Pharma operates in the Biopharma industry.
Where is Artios Pharma based?+
Artios Pharma is headquartered in United Kingdom.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026